References
- IlicDNeubergerMMDjulbegovicMDahmPScreening for prostate cancerCochrane Database Syst Rev20131CD004720
- EdgeSBByrdDRComptonCCFritzAGGreeneFLTrottiAAmerican Joint Committee on Cancer Staging Manual7th edNew YorkSpringer2010
- WangMCValenzuelaLAMurphyGPChuTMPurification of a human prostate specific antigenInvest Urol197917215916389106
- StameyTAYangNHayARMcNealJEFreihaFSRedwineEProstate-specific antigen as a serum marker for adenocarcinoma of the prostateN Engl J Med1987317159099162442609
- WalterLCBertenthalDLindquistKKonetyBRPSA screening among elderly men with limited life expectanciesJAMA2006296192336234217105796
- ItoKProstate cancer in Asian menNat Rev Urol201411419721224595118
- NCCN guideline PCaNational Comprehensive Cancer Network “NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer Version 2.2014”Fort Washington, PA20132014
- MahalBAAizerAAEfstathiouJANguyenPLAssociation of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancerCancer20161221788326371600
- BrandtJGarneJPTengrupIManjerJAge at diagnosis in relation to survival following breast cancer: a cohort studyWorld J Surg Oncol20151313325889186
- BechisSKCarrollPRCooperbergMRImpact of age at diagnosis on prostate cancer treatment and survivalJ Clin Oncol201129223524121135285
- HugginsCHodgesCVStudies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941J Urol2002168191212050481
- HarrisWPMostaghelEANelsonPSMontgomeryBAndrogen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNat Clin Pract Urol200962768519198621
- KaisaryAVTyrrellCJPeelingWBGriffithsKComparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinomaBr J Urol19916755025081828183
- VogelzangNJChodakGWSolowayMSGoserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study GroupUrology19954622202267624991
- SunMChoueiriTKHamnvikOPComparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapyJAMA Oncol20162450050726720632
- OefeleinMGFengAScolieriMJRicchiuttiDResnickMIReassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology20005661021102411113751
- MercaderMSenguptaSBodnerBKEarly effects of pharmacological androgen deprivation in human prostate cancerBJU Int2007991606717227493
- MontironiRMagi-GalluzziCMuzzonigroGPreteEPolitoMFabrisGEffects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinomaJ Clin Pathol199447109069137525657
- MoroteJEsquenaSAbascalJMFailure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancerUrol Int200677213513816888418
- MoroteJOrsolaAPlanasJRedefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapyJ Urol20071784 Pt 11290129517698136
- OefeleinMGCornumRFailure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithmJ Urol20001643 Pt 172672910953134
- SasakiTOnishiTHoshinaANadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasisProstate Cancer Prostatic Dis201114324825221502970
- TomiokaATanakaNYoshikawaMNadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancerBMC Urol20141413324773608
- CeresoliGLDe VincenzoFSautaMGBonomiMZucaliPARole of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancerQ J Nucl Med Mol Imaging201559437438026222275
- MillerRESweeneyCJChemotherapy for metastatic castrate-sensitive prostate cancerProstate Cancer and Prostatic Dis2016192139144